WO2001058483A3 - METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES - Google Patents

METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES Download PDF

Info

Publication number
WO2001058483A3
WO2001058483A3 PCT/US2001/004020 US0104020W WO0158483A3 WO 2001058483 A3 WO2001058483 A3 WO 2001058483A3 US 0104020 W US0104020 W US 0104020W WO 0158483 A3 WO0158483 A3 WO 0158483A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
animal
methods
present
infections
Prior art date
Application number
PCT/US2001/004020
Other languages
French (fr)
Other versions
WO2001058483A2 (en
Inventor
Ronald P Taylor
Margaret A Lindorfer
William M Sutherland
Joanna B Goldberg
Original Assignee
Univ Virginia
Ronald P Taylor
Margaret A Lindorfer
William M Sutherland
Joanna B Goldberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia, Ronald P Taylor, Margaret A Lindorfer, William M Sutherland, Joanna B Goldberg filed Critical Univ Virginia
Priority to AU2001234925A priority Critical patent/AU2001234925A1/en
Priority to CA002400488A priority patent/CA2400488A1/en
Priority to JP2001557591A priority patent/JP2003522159A/en
Priority to EP01907104A priority patent/EP1257583A2/en
Publication of WO2001058483A2 publication Critical patent/WO2001058483A2/en
Publication of WO2001058483A3 publication Critical patent/WO2001058483A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the treatment and prevention of viral infections, microbial infections, and septic shock by the administration of anti-C3b(i) antibodies. The present invention also relates to methods of treating and preventing viral infection, microbial infection, or septic shock in an animal comprising administering to said animal IgG antibodies, IgM antibodies and/or complement components in combination with antibodies immunospecific for C3b(i). The present invention also relates methods of treating and preventing viral infection or microbial infection in an animal comprising administrating said animal antibodies that immunospecifically bind to one or more viral antigens or microbial antigens, respectively, in combination with antibodies immunospecific for C3b(i). The present invention further relates methods of treating and preventing septic shock in an animal comprising administrating said animal antibodies that immunospecifically bind to lipopolysaccharide, an endotoxin or a constituent of the outer wall of a gram negative bacteria in combination with antibodies immunospecific for C3b(i).
PCT/US2001/004020 2000-02-08 2001-02-08 METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES WO2001058483A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001234925A AU2001234925A1 (en) 2000-02-08 2001-02-08 Methods for the prevention and treatment of infections using anti-C3b(i) antibodies
CA002400488A CA2400488A1 (en) 2000-02-08 2001-02-08 Methods for the prevention and treatment of infections using anti-c3b(i) antibodies
JP2001557591A JP2003522159A (en) 2000-02-08 2001-02-08 Method for prevention and treatment of infection using anti-C3b (i) antibody
EP01907104A EP1257583A2 (en) 2000-02-08 2001-02-08 METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18114300P 2000-02-08 2000-02-08
US60/181,143 2000-02-08
US72462100A 2000-11-28 2000-11-28
US09/724,621 2000-11-28

Publications (2)

Publication Number Publication Date
WO2001058483A2 WO2001058483A2 (en) 2001-08-16
WO2001058483A3 true WO2001058483A3 (en) 2002-04-18

Family

ID=26876927

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004020 WO2001058483A2 (en) 2000-02-08 2001-02-08 METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES

Country Status (5)

Country Link
EP (1) EP1257583A2 (en)
JP (1) JP2003522159A (en)
AU (1) AU2001234925A1 (en)
CA (1) CA2400488A1 (en)
WO (1) WO2001058483A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
JP2004532626A (en) * 2001-03-15 2004-10-28 エリューシス セラピューティクス，インコーポレーテッド Polyclonal populations of bispecific molecules, and methods for their production and use
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CA2524534C (en) * 2003-05-15 2012-12-11 Sek Chung Fung Methods and compositions for the prevention and treatment of sepsis
PL1685251T3 (en) 2003-10-10 2014-07-31 Powderject Vaccines Inc Nucleic acid constructs
EP2560677A4 (en) * 2010-04-23 2013-09-11 Probiotec Ltd Cold treatment
CN110865182B (en) * 2019-11-19 2023-06-27 东莞市东阳光诊断产品有限公司 Blocking agent and application thereof in immunodetection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006344A1 (en) * 1986-04-11 1987-10-22 Nilsson Ulf R Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof
WO2000015259A1 (en) * 1998-09-10 2000-03-23 The University Of Virginia Patent Foundation Antibodies to c3b(i) for delivery of diagnostic and therapeutic agents to cancer cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006344A1 (en) * 1986-04-11 1987-10-22 Nilsson Ulf R Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof
WO2000015259A1 (en) * 1998-09-10 2000-03-23 The University Of Virginia Patent Foundation Antibodies to c3b(i) for delivery of diagnostic and therapeutic agents to cancer cells

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CAMPBELL G A ET AL: "Mechanisms of binding of Brucella abortus to mononuclear phagocytes from cows naturally resistant or susceptible to brucellosis.", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 41, no. 3-4, 1994, pages 295 - 306, XP001005480, ISSN: 0165-2427 *
DEMPSEY PW ET AL: "C3d OF COMPLEMENT AS A MOLECULAR ADJUVANT: BRIDGING INATE AND ACQUIRED IMMUNITY", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 271, 19 January 1996 (1996-01-19), pages 348 - 350, XP002095252, ISSN: 0036-8075 *
H HUEMER ET AL: "Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein", IMMUNOLOGY,GB,OXFORD, vol. 79, no. 4, 1 August 1993 (1993-08-01), pages 639 - 647, XP002091631, ISSN: 0019-2805 *
KRETTLI A U ET AL: "BINDING OF COMPLEMENT C-3 FRAGMENTS TO THE TRYPANOSOMA-CRUZI SURFACE IN THE ABSENCE OF SPECIFIC ANTIBODIES AND WITHOUT ACTIVATION OF THE COMPLEMENT CASCADE", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 62, no. 2, 1985, pages 270 - 277, XP001000367, ISSN: 0009-9104 *
MCCORMICK L.L. ET AL.: "Bispecific Antibodies Overcome the Opsonin-Receptor Mismatch of Cystic Fibrosis In Vitro", J. IMMUNOLOGY, vol. 158, 1997, pages 3474 - 3482, XP000999281 *
NEWMAN S L ET AL: "DEPOSITION OF COMPLEMENT C-3B AND COMPLEMENT I-C-3B ONTO PARTICULATE ACTIVATORS OF THE HUMAN COMPLEMENT SYSTEM QUANTITATION WITH MONOCLONAL ANTIBODIES TO HUMAN COMPLEMENT C-3", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 161, no. 6, 1985, pages 1414 - 1431, XP001000368, ISSN: 0022-1007 *
TAMERIUS J D ET AL: "DETECTION OF A NEOANTIGEN ON HUMAN COMPLEMENT C-3BI AND C-3D BY MONOCLONAL ANTIBODY", JOURNAL OF IMMUNOLOGY, vol. 135, no. 3, 1985, pages 2015 - 2019, XP001000801, ISSN: 0022-1767 *
VAPORCIYAN ARA A ET AL: "Enhanced generation of O-2- by human neutrophils via a complement iC3b/Mac-1 interaction.", BIOLOGICAL SIGNALS, vol. 2, no. 3, 1993, pages 126 - 135, XP001000394, ISSN: 1016-0922 *

Also Published As

Publication number Publication date
AU2001234925A1 (en) 2001-08-20
CA2400488A1 (en) 2001-08-16
JP2003522159A (en) 2003-07-22
WO2001058483A2 (en) 2001-08-16
EP1257583A2 (en) 2002-11-20

Similar Documents

Publication Publication Date Title
WO2002043570A3 (en) METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES
US5707627A (en) Methods and compositions for the direct concentrated delivery of passive immunity
DK1629850T4 (en) Nutritional composition containing indigestible oligosaccharides
IL158088A (en) Use of an antibody that binds to an activation inducible lymphocyte immunomodulatory molecule (ailim) in the manufacture of a pharmaceutical composition for suppressing, treating or preventing an inflammatory bowel disease
DE69940371D1 (en) BETA-GLUCAN CONTAINING COMPOSITIONS AND SPECIFIC IMMUNOGLOBULINS
LU91928I2 (en) Ipilimumab and its pharmaceutically acceptable derivatives (YERVOY®)
RU2012133522A (en) NEW USE OF IL-1 BETA COMPOUNDS
CY1109817T1 (en) OLIGO-BETA (1,3) -GLUCAN AND MONOCLONIC ANTIBODIES AGAINST CANCER
NO20063105L (en) Device and method of administration of therapeutic agents
AU1794601A (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
WO2001058483A3 (en) METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
BR0002577A (en) Oral suspensions of trovafloxacin
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
WO2005030109A3 (en) Regimen for the administration of rifamycin-class antibiotics
Elsey et al. Pasteurella multocida peritonitis in an HIV-positive patient on continuous cycling peritoneal dialysis
DE69426767D1 (en) Anti idiotypic antibodies to gonococci and methods and compositions using them.
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
Felts et al. Locally Delivered Antibodies Combined with Systemic Antibiotics Confer Synergistic Protection a gainst Antibiotic-Resistant Burn Wound Infection
WO2005056601A3 (en) Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
WO2004050120A3 (en) Treatment of prion-induced diseases by administration fo anti-prion antibodies
WO2000041526A3 (en) Use of s-triazines for treating apicomplexan parasitic infections
WO1990013660A3 (en) Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections
EP1334131A4 (en) Monoclonal antibodies to the map protein and method of use in treating or preventing infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2400488

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 557591

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001907104

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001234925

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001907104

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001907104

Country of ref document: EP